International Journal of Aesthetic Medicine and Health

Utilization stem cells and antiangiogenic treatment of age-related macular degeneration (AMD)

Review article of International Journal of Aesthetic Medicine and Health Utilization stem cells and antiangiogenic treatment of age-related macular degeneration (AMD) Silva, V.M1, Santos, G.S2, Silva, J.F.S3, Santos, G.M4, Wanderley, M.C.A5, Godone, R.L.N6 1,2,3,4 Student of Biomedicine Course - UNINASSAU- Caruaru; 5, 6 Professor in Biomedicine Course - UNINASSAU- Caruaru. Introduction: Age-related macular degeneration (AMD) is an increasingly common pathology due to the general aging of the population, and has assumed the dimension of a true public health problem. Currently, the applications of cellular therapies are viable in the repair of the corneous tissue. Angiogenesis inhibitors, however, are a class of drugs most commonly used to block the proliferation of new blood vessels. Advances in the study with stem cells and antiangiogenic have provided expectations in the scientific community, as to its use in regeneration of tissues damaged by degenerative diseases. Objective: To relate the advances in research on AMD with the use stem cells and antiangiogenic as an effective treatment for this pathology. Methodology: Electronic data platforms (MEDLINE, PubMed, Scopus) were consulted from 2011 to 2016, using descriptors: “stem cells”, “macular degeneration”, “AMD” and “antiangiogenic”. Results and Discussion: Clinical studies in adult rats showed that stem cells derived from bone marrow applied to the ocular tissue, activated neurological cells called astrocytes, contributed to the regeneration of this tissue due to trauma. The results correlating antiangiogenic as Bevacizumab were included by ANVISA (Agência Nacional de Vigilância Sanitária) in 2011. Therefore, due to its inhibitory effect of angiogenesis, it has been used in ophthalmologic degenerative diseases such as AMD. The regeneration of ocular tissues, through therapy with stem cells presents problems to be solved, by the different types of embryonic tissues. This differentiation should establish criteria for the best choice of the origin of stem cells. Bevacizumab has been used in the ...

Manuscript Title: The title should be a brief phrase.

Author Information: List full names and affiliation of all authors, including Emails and phone numbers of corresponding author.

Abstract: The abstract should be less than 500 words. Following abstract, a list of keywords and abbreviations should be added. The keywords should be no more than 10. Abbreviation are only used for non standard and long terms.

Introduction: The introduction should included a clear statement of current problems.

Materials and Methods: This section should be clearly described.

Results and discussion: Authors may put results and discussion into a single section or show them separately.

Acknowledgement: This section includes a brief acknowledgment of people, grant details, funds

References: References should be listed in a numbered citation order at the end of the manuscript. DOIs and links to referenced articles should be added if available. Abstracts and talks for conferences or papers not yet accepted should not be cited. Examples Published Papers: 

1. Avinaba Mukherjee, Sourav Sikdar, Anisur Rahman Khuda-Bukhsh. Evaluation of ameliorative potential of isolated flavonol fractions from Thuja occidentalis in lung cancer cells and in Benzo(a) pyrene induced lung toxicity in mice. International Journal of Traditional and Complementary Medicine, 2016; 1(1): 0001-0013. 
2. Vikas Gupta, Parveen Bansal, Junaid Niazi, Kamlesh Kohli, Pankaj Ghaiye. Anti-anxiety Activity of Citrus paradisi var. duncan Extracts in Swiss Albino Mice-A Preclinical Study. Journal of Herbal Medicine Research, 2016; 1(1): 0001-0006.

Tables and figures: Tables should be used at a minimum with a short descriptive title. The preferred file formats for Figures/Graphics are GIF, TIFF, JPEG or PowerPoint.

Proofreading and Publication: A proof will be sent to the corresponding author before publication. Authors should carefully read the proof to avoid any errors and return the proof to the editorial office. Editorial office will publish the article shortly and send a notice to authors with the links of the paper.

Open Access

International Journal of Aesthetic Medicine and Health (ISSN:2637-630X; DOI:10.28933/IJAMH) is a peer reviewed open access journal publishing research manuscripts, review articles, editorials, letters to the editor in Aesthetic Medicine and Health (Indexing details).

Peer Review

To ensure the quality of the publications, all submitted manuscripts will be peer-reviewed by invited experts in the field. The decisions of editors will be made based on the comments of the reviewers.

Rapid Publication

Time to first decision: within 2 days for initial decision without review, 18 days with review; Time to publication: Accepted articles will be published online within 2 days, and final corrected versions by authors will be accessible within 5 days.  More details....

Rapid Response Team

Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer your questions shortly.

International Journal of Aesthetic Medicine


Note: Please compress all documents (manuscript, cover letter et al.,. ) into one .Zip file and then upload the Zip file.